Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 7
2005 7
2006 5
2007 10
2008 8
2009 8
2010 7
2011 8
2012 6
2013 9
2014 11
2015 16
2016 14
2017 9
2018 13
2019 14
2020 18
2021 24
2022 11
2023 11
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

194 results

Results by year

Filters applied: . Clear all
Page 1
Extended interval dosing with ocrelizumab in multiple sclerosis.
Novak F, Bajwa HM, Østergaard K, Berg JM, Madsen JS, Olsen DA, Urbonaviciute I, Illes Z, Stilund ML, Romme Christensen J, Bramow S, Sellebjerg F, Sejbaek T. Novak F, et al. Among authors: illes z. Mult Scler. 2024 Apr 22:13524585241245296. doi: 10.1177/13524585241245296. Online ahead of print. Mult Scler. 2024. PMID: 38646949
Prognostic factors for disease activity in newly diagnosed teriflunomide-treated patients with multiple sclerosis: a nationwide Danish study.
Mahler MR, Magyari M, Pontieri L, Elberling F, Holm RP, Weglewski A, Poulsen MB, Storr LK, Bekyarov PA, Illes Z, Kant M, Sejbaek T, Stilund ML, Rasmussen PV, Brask M, Urbonaviciute I, Sellebjerg F. Mahler MR, et al. Among authors: illes z. J Neurol Neurosurg Psychiatry. 2024 Apr 3:jnnp-2023-333265. doi: 10.1136/jnnp-2023-333265. Online ahead of print. J Neurol Neurosurg Psychiatry. 2024. PMID: 38569873
High temperature requirement A1 and macrophage migration inhibitory factor in the cerebrospinal fluid; a potential marker of conversion from relapsing-remitting to secondary progressive multiple sclerosis.
Hjæresen S, Benedikz E, Sejbaek T, Axelsson M, Novakova L, Zhang M, Lycke J, Illes Z, Fex-Svenningsen Å. Hjæresen S, et al. Among authors: illes z. J Neurol Sci. 2024 Feb 15;457:122888. doi: 10.1016/j.jns.2024.122888. Epub 2024 Jan 14. J Neurol Sci. 2024. PMID: 38278096 Free article.
Discontinuation of dimethyl fumarate in multiple sclerosis - a nationwide study.
Roar M, Nielsen ARH, Berg JM, Sirakov G, Stilund M, Schäfer J, Ratzer R, Frederiksen J, Asgari N, Ashna SN, Jensen HB, Kant M, Theódorsdóttir Á, Illes Z, Sellebjerg F, Magyari M, Schlosser LM, Nordborg H, Wergeland S, Sejbaek T. Roar M, et al. Among authors: illes z. Mult Scler Relat Disord. 2023 Dec;80:105127. doi: 10.1016/j.msard.2023.105127. Epub 2023 Nov 5. Mult Scler Relat Disord. 2023. PMID: 37956521
194 results